Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva
Date:7/23/2008

DETROIT, July 23 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) announced the resignation as a Director of the Company of Jitendra N. Doshi and the appointment as a Director of the Company of Gurpartap ("GP") Singh Sachdeva, the Senior Vice President - Business Strategies of the Company, effective July 22, 2008.

Prior to his appointment as Senior Vice President of Business Strategies in July 2007, Mr. Singh served as Vice President - Sales and Marketing (September 2003 to July 2007) and National Sales and Marketing Manager (September 2000 to September 2003) of the Company. From May 1998 to September 2000, Mr. Singh was the Manager of Bulk Drugs for Sun Pharmaceutical Industries Limited.

Daniel H. Movens, the Company's Chief Executive Officer, noted that Dr. Doshi had an extensive history of dedicated service to the Company stating that "Mr. Doshi has provided invaluable service to the Company as an executive officer, including CEO, and as a Director, since 2001. His efforts greatly contributed to the success we have achieved." Mr. Doshi continues to serve as an Executive Director for Sun Pharmaceutical Industries Inc.

Mr. Movens continued, "We are very pleased to welcome Mr. Singh to the Board. His experience, depth of knowledge and accomplished background should provide us with good guidance into the foreseeable future. We are certain that he will bring to the Board the same energy and sound judgment that he has shown as an executive officer of the Company."

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Item 1A to the Corporation's annual report on Form 10-K, and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
2. Sonus Pharmaceuticals Receives Favorable NASDAQ Decision
3. Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
4. Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering
5. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
6. Worlds Top 20 Pharmaceutical Companies Deploy Revolutionary H-Cube(R) From ThalesNano Inc.
7. Amylin Pharmaceuticals to Webcast Second Quarter Results
8. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
9. ViroPharma To Acquire Lev Pharmaceuticals
10. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
11. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):